Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

RCT (n=668, China) found donafenib, a novel multikinase inhibitor & deuterated sorafenib derivative linked to superior overall survival vs sorafenib (12.1 vs 10.3 months, HR 0.831, 95%CI 0.699-0.988) but no significant differences in progression free survival or response rates.

Journal of Clinical Oncology